---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-24-086476"
form_type: "8-K"
ticker: "CUE"
cik: "0001645460"
company_name: "Cue Biopharma, Inc."
filed_at: "2024-07-25T23:59:59+00:00"
generated_at: "2026-05-31T16:18:44.400843+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.7
calibrated_materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Cue Biopharma restructures, cuts workforce 25%, extends cash runway to mid-2025

## Summary
- Reduces workforce by ~25% across R&D and G&A; CEO Daniel Passeri takes 50% salary reduction, execs forgo 2023 bonuses.
- Prioritizes autoimmune programs CUE-401 (partnered with Ono) and CUE-501; retains oncology CUE-101/102 Phase 1 data maturation.
- Projects FY2025 annual cash burn of ~$30M, an ~25% reduction in operating expenses.
- Expects extended cash runway into mid-2025; actively pursuing partnerships for oncology programs.
- Restructuring effective July 24, 2024; aims to reduce capital requirements and strengthen operational efficiencies.

## SEC filing metadata
- accession: 0000950170-24-086476
- form_type: 8-K
- ticker: CUE
- cik: 0001645460
- company_name: Cue Biopharma, Inc.
- filed_at: 2024-07-25T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.7
- calibrated_materiality_score: 0.7
- confidence: high
- sec_items: 5.02, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1645460/000095017024086476/0000950170-24-086476-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1645460/000095017024086476/cue-20240724.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-24-086476
- JSON: https://secwatch.observer/filing/0000950170-24-086476.json
- Plain text: https://secwatch.observer/filing/0000950170-24-086476.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.